Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

1.

The place of PD-1 inhibitors in melanoma management.

Bowyer S, Lorigan P.

Lancet Oncol. 2015 Jun 23. pii: S1470-2045(15)00094-7. doi: 10.1016/S1470-2045(15)00094-7. [Epub ahead of print] No abstract available.

PMID:
26115798
2.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

PMID:
26030178
3.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

PMID:
25891173
4.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
5.

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.

Howell M, Lee R, Bowyer S, Fusi A, Lorigan P.

Lung Cancer. 2015 May;88(2):117-23. doi: 10.1016/j.lungcan.2015.02.007. Epub 2015 Feb 16. Review.

PMID:
25776466
6.

Expanded access programmes: patient interests versus clinical trial integrity.

Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM.

Lancet Oncol. 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29. No abstract available.

PMID:
25638540
7.

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11.

8.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

9.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF.

J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10.

PMID:
25385727
10.

Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.

Hudson AM, Yates T, Li Y, Trotter EW, Fawdar S, Chapman P, Lorigan P, Biankin A, Miller CJ, Brognard J.

Cancer Res. 2014 Nov 15;74(22):6390-6. doi: 10.1158/0008-5472.CAN-14-1020. Epub 2014 Sep 25.

11.

Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma.

Stamataki Z, Brunton L, Lorigan P, Green AC, Newton-Bishop J, Molassiotis A.

Support Care Cancer. 2015 Mar;23(3):779-89. doi: 10.1007/s00520-014-2414-x. Epub 2014 Sep 5.

PMID:
25189151
12.

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Girotti MR, Saturno G, Lorigan P, Marais R.

Mol Oncol. 2014 Sep 12;8(6):1140-58. doi: 10.1016/j.molonc.2014.07.027. Epub 2014 Aug 15. Review.

PMID:
25178978
13.

Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma.

Molassiotis A, Brunton L, Hodgetts J, Green AC, Beesley VL, Mulatero C, Newton-Bishop JA, Lorigan P.

Ann Oncol. 2014 Oct;25(10):2052-8. doi: 10.1093/annonc/mdu366. Epub 2014 Jul 31.

PMID:
25081900
14.

Vemurafenib-induced nonautoimmune haemolytic anaemia.

Fusi A, Hodgetts J, Dennis M, Lorigan P.

Melanoma Res. 2014 Aug;24(4):418-9. doi: 10.1097/CMR.0000000000000094. No abstract available.

PMID:
24992630
15.

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A.

Ann Oncol. 2015 Jan;26(1):33-9. doi: 10.1093/annonc/mdu207. Epub 2014 Jun 6.

PMID:
24907634
16.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

17.

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ.

Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26.

18.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R.

Sci Signal. 2014 Mar 25;7(318):ra30. doi: 10.1126/scisignal.2004815.

PMID:
24667377
19.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU.

Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8.

PMID:
24609989
20.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR.

Ann Oncol. 2014 May;25(5):968-74. doi: 10.1093/annonc/mdu054. Epub 2014 Feb 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk